Cargando…

12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus

BACKGROUND: Previous publications have proved the effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal pleural empyema (PnPE) in children, with little emergence of other pathogens. We searched the literature to establish whether PCV13 reduces PnPE, and to identify ot...

Descripción completa

Detalles Bibliográficos
Autores principales: Chacon-Cruz, Enrique, Rivas-Landeros, Rosa Maria, Volker-Soberanes, Maria Luisa, Lopatynsky-Reyes, Erika Zoe, Becka, Chandra, Alvelais-Palacios, Jorge Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448099/
https://www.ncbi.nlm.nih.gov/pubmed/30984396
http://dx.doi.org/10.1177/2049936119839312
_version_ 1783408631464591360
author Chacon-Cruz, Enrique
Rivas-Landeros, Rosa Maria
Volker-Soberanes, Maria Luisa
Lopatynsky-Reyes, Erika Zoe
Becka, Chandra
Alvelais-Palacios, Jorge Arturo
author_facet Chacon-Cruz, Enrique
Rivas-Landeros, Rosa Maria
Volker-Soberanes, Maria Luisa
Lopatynsky-Reyes, Erika Zoe
Becka, Chandra
Alvelais-Palacios, Jorge Arturo
author_sort Chacon-Cruz, Enrique
collection PubMed
description BACKGROUND: Previous publications have proved the effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal pleural empyema (PnPE) in children, with little emergence of other pathogens. We searched the literature to establish whether PCV13 reduces PnPE, and to identify other pathogens causing pleural empyemas (PEs). MATERIAL AND METHODS: From October 2005 to January 2018 (12.3 years) we performed active surveillance for all cases of PE at the General Hospital of Tijuana, Mexico. Isolates from pleural fluid (PF) were identified by conventional culture, and since 2014, polymerase chain reaction (PCR) was added for all culture-negative PFs. Streptococcus pneumoniae serotypes were detected by either Quellung reaction (Statens Serum Institute®) or PCR. Clinical, imagenological, laboratorial and microbiological evaluation was performed on each patient. Statistical analysis was purely descriptive. RESULTS: A total of 64 PEs were identified (5.28/year). Median age was 51 months (1–191), hospitalization days 18 (4–35). Decortication was performed in 42%, and two children died (3.2%). Bacterial identification was obtained from 51 (80%). S. pneumoniae was the leading cause (29 = 56.8%), followed by Staphylococcus aureus (14 = 27.4%), Streptococcus pyogenes (3–5 = 9%) and others (5 = 9.8%). PCV13 was initiated in May 2012, and its impact on serotype-specific PnPE was 81% (much fewer than serotype 3) and for all PnPE 56.1%; however, for all PE −2.1% due to an increase of PE caused by S. aureus for all but one methicillin-resistant S. aureus (MRSA). CONCLUSIONS: Following 12.3 years of active surveillance, PCV13 has shown impact on both serotype-specific and all PnPEs; however, an increase of PEs by MRSA has emerged. Continuous surveillance is crucial to establish whether this epidemiological finding is transitory or not.
format Online
Article
Text
id pubmed-6448099
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-64480992019-04-12 12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus Chacon-Cruz, Enrique Rivas-Landeros, Rosa Maria Volker-Soberanes, Maria Luisa Lopatynsky-Reyes, Erika Zoe Becka, Chandra Alvelais-Palacios, Jorge Arturo Ther Adv Infect Dis Original Research BACKGROUND: Previous publications have proved the effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal pleural empyema (PnPE) in children, with little emergence of other pathogens. We searched the literature to establish whether PCV13 reduces PnPE, and to identify other pathogens causing pleural empyemas (PEs). MATERIAL AND METHODS: From October 2005 to January 2018 (12.3 years) we performed active surveillance for all cases of PE at the General Hospital of Tijuana, Mexico. Isolates from pleural fluid (PF) were identified by conventional culture, and since 2014, polymerase chain reaction (PCR) was added for all culture-negative PFs. Streptococcus pneumoniae serotypes were detected by either Quellung reaction (Statens Serum Institute®) or PCR. Clinical, imagenological, laboratorial and microbiological evaluation was performed on each patient. Statistical analysis was purely descriptive. RESULTS: A total of 64 PEs were identified (5.28/year). Median age was 51 months (1–191), hospitalization days 18 (4–35). Decortication was performed in 42%, and two children died (3.2%). Bacterial identification was obtained from 51 (80%). S. pneumoniae was the leading cause (29 = 56.8%), followed by Staphylococcus aureus (14 = 27.4%), Streptococcus pyogenes (3–5 = 9%) and others (5 = 9.8%). PCV13 was initiated in May 2012, and its impact on serotype-specific PnPE was 81% (much fewer than serotype 3) and for all PnPE 56.1%; however, for all PE −2.1% due to an increase of PE caused by S. aureus for all but one methicillin-resistant S. aureus (MRSA). CONCLUSIONS: Following 12.3 years of active surveillance, PCV13 has shown impact on both serotype-specific and all PnPEs; however, an increase of PEs by MRSA has emerged. Continuous surveillance is crucial to establish whether this epidemiological finding is transitory or not. SAGE Publications 2019-04-03 /pmc/articles/PMC6448099/ /pubmed/30984396 http://dx.doi.org/10.1177/2049936119839312 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Chacon-Cruz, Enrique
Rivas-Landeros, Rosa Maria
Volker-Soberanes, Maria Luisa
Lopatynsky-Reyes, Erika Zoe
Becka, Chandra
Alvelais-Palacios, Jorge Arturo
12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus
title 12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus
title_full 12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus
title_fullStr 12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus
title_full_unstemmed 12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus
title_short 12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus
title_sort 12 years active surveillance for pediatric pleural empyema in a mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant staphylococcus aureus
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448099/
https://www.ncbi.nlm.nih.gov/pubmed/30984396
http://dx.doi.org/10.1177/2049936119839312
work_keys_str_mv AT chaconcruzenrique 12yearsactivesurveillanceforpediatricpleuralempyemainamexicanhospitaleffectivenessofpneumococcal13valentconjugatevaccineandearlyemergenceofmethicillinresistantstaphylococcusaureus
AT rivaslanderosrosamaria 12yearsactivesurveillanceforpediatricpleuralempyemainamexicanhospitaleffectivenessofpneumococcal13valentconjugatevaccineandearlyemergenceofmethicillinresistantstaphylococcusaureus
AT volkersoberanesmarialuisa 12yearsactivesurveillanceforpediatricpleuralempyemainamexicanhospitaleffectivenessofpneumococcal13valentconjugatevaccineandearlyemergenceofmethicillinresistantstaphylococcusaureus
AT lopatynskyreyeserikazoe 12yearsactivesurveillanceforpediatricpleuralempyemainamexicanhospitaleffectivenessofpneumococcal13valentconjugatevaccineandearlyemergenceofmethicillinresistantstaphylococcusaureus
AT beckachandra 12yearsactivesurveillanceforpediatricpleuralempyemainamexicanhospitaleffectivenessofpneumococcal13valentconjugatevaccineandearlyemergenceofmethicillinresistantstaphylococcusaureus
AT alvelaispalaciosjorgearturo 12yearsactivesurveillanceforpediatricpleuralempyemainamexicanhospitaleffectivenessofpneumococcal13valentconjugatevaccineandearlyemergenceofmethicillinresistantstaphylococcusaureus